Our results suggest that besides for its insulin sensitivity functions, pioglitazone reduces fibrosis and could be repurposed as an agent for HCC chemoprevention especially in the setting of NASH. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.